TITLE
Anti-CTLA-4 immunotherapy effect on αSMA+ myofibroblast late-depleted pancreatic ductal adenocarcinoma model

SUMMARY
Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 6 weeks of age for 10 days or less to deplete αSMA+ myofibroblasts and treated with anti-CTLA4. Results provide insight into molecular basis of anti-CTLA4 therapy in PDAC.

ORGANISM
Mus musculus

